M C Zanarini1. 1. Harvard Medical School, Boston, MA, USA. zanarini@mclean.harvard.edu
Abstract
OBJECTIVE: Psychotherapy is considered the primary treatment for borderline personality disorder (BPD). Currently, there are four comprehensive psychosocial treatments for BPD. Two of these treatments are considered psychodynamic in nature: mentalization-based treatment and transference-focused psychotherapy. The other two are considered to be cognitive-behavioral in nature: dialectical behavioral therapy and schema-focused therapy. METHOD: A review of the relevant literature was conducted. RESULTS: Each of these lengthy and complex psychotherapies significantly reduces the severity of borderline psychopathology or at least some aspects of it, particularly physically self-destructive acts. CONCLUSION: Comprehensive, long-term psychotherapy can be a useful form of treatment for those with BPD. However, less intensive and less costly forms of treatment need to be developed.
OBJECTIVE: Psychotherapy is considered the primary treatment for borderline personality disorder (BPD). Currently, there are four comprehensive psychosocial treatments for BPD. Two of these treatments are considered psychodynamic in nature: mentalization-based treatment and transference-focused psychotherapy. The other two are considered to be cognitive-behavioral in nature: dialectical behavioral therapy and schema-focused therapy. METHOD: A review of the relevant literature was conducted. RESULTS: Each of these lengthy and complex psychotherapies significantly reduces the severity of borderline psychopathology or at least some aspects of it, particularly physically self-destructive acts. CONCLUSION: Comprehensive, long-term psychotherapy can be a useful form of treatment for those with BPD. However, less intensive and less costly forms of treatment need to be developed.
Authors: Mary C Zanarini; Frances R Frankenburg; D Bradford Reich; Kenneth R Silk; James I Hudson; Lauren B McSweeney Journal: Am J Psychiatry Date: 2007-06 Impact factor: 18.112
Authors: Nancee Blum; Don St John; Bruce Pfohl; Scott Stuart; Brett McCormick; Jeff Allen; Stephan Arndt; Donald W Black Journal: Am J Psychiatry Date: 2008-02-15 Impact factor: 18.112
Authors: D S Bender; R T Dolan; A E Skodol; C A Sanislow; I R Dyck; T H McGlashan; M T Shea; M C Zanarini; J M Oldham; J G Gunderson Journal: Am J Psychiatry Date: 2001-02 Impact factor: 18.112
Authors: Andrew E Skodol; John G Gunderson; Thomas H McGlashan; Ingrid R Dyck; Robert L Stout; Donna S Bender; Carlos M Grilo; M Tracie Shea; Mary C Zanarini; Leslie C Morey; Charles A Sanislow; John M Oldham Journal: Am J Psychiatry Date: 2002-02 Impact factor: 18.112
Authors: Bridget F Grant; S Patricia Chou; Risë B Goldstein; Boji Huang; Frederick S Stinson; Tulshi D Saha; Sharon M Smith; Deborah A Dawson; Attila J Pulay; Roger P Pickering; W June Ruan Journal: J Clin Psychiatry Date: 2008-04 Impact factor: 4.384
Authors: Igor Weinberg; Elsa Ronningstam; Mark J Goldblatt; Mark Schechter; John T Maltsberger Journal: Curr Psychiatry Rep Date: 2011-02 Impact factor: 5.285
Authors: Federico Amianto; Andrea Ferrero; Andrea Pierò; Elisabetta Cairo; Giuseppe Rocca; Barbara Simonelli; Simona Fassina; Giovanni Abbate-Daga; Secondo Fassino Journal: BMC Psychiatry Date: 2011-11-21 Impact factor: 3.630
Authors: Paul Moran; Rohan Borschmann; Clare Flach; Barbara Barrett; Sarah Byford; Joanna Hogg; Morven Leese; Kim Sutherby; Claire Henderson; Diana Rose; Mike Slade; George Szmukler; Graham Thornicroft Journal: Trials Date: 2010-02-23 Impact factor: 2.279
Authors: G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young Journal: J Psychopharmacol Date: 2016-03-15 Impact factor: 4.153